enrolment – Page 3 – Communicable Diseases Research

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

HIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험

Clinical Trial

Published on 2022-05-012022-09-12
Journal: The Lancet. HIV [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19

COVID-19로 입원하지 않은 환자의 조기 치료를 위한 Casirivimab/Imdevimab 및 Bamlanivimab/Etesevimab의 효과를 비교하기 위한 관찰 데이터의 표적 시험 에뮬레이션

Clinical Trial

Published on 2022-04-202022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 임상, 진단,

[키워드] adjusted allocation Alpha Analysis ANCOVA bamlanivimab bamlanivimab/etesevimab baseline carried Casirivimab casirivimab/imdevimab Combination Comparative analysis COVID-19 Cox model Ct value cycle threshold death Delta determine early treatment early treatment for COVID-19 Effectiveness enrolment etesevimab evaluated Evidence Factor Factors high viral load Hospitalization Imdevimab in viral Intervention Logistic regression mAb mAbs Mild-to-moderate Model Modification monoclonal antibodies monoclonal antibody Nasopharyngeal swab negative RT-PCR not used Observational data occurred outcome Outpatient outpatients Patient PCR test Primary outcome Probability progression reduced risk reduction Relative risk risk reduction RT-PCR test SARS-CoV-2 Stratification subject target Treatment Trial two group two groups vaccination variants variants of concern Viral Viral load viral load reduction virological response VOCs was measured was used were used
[DOI] 10.3389/fimmu.2022.868020 PMC 바로가기 [Article Type] Clinical Trial

Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study

SARS-CoV-2 감염이 확인된 백신 접종을 하지 않은 무증상 및 증상이 있는 가구 구성원으로부터 SARS-CoV-2의 가구 전파: 항체 감시 연구

Article

Published on 2022-04-122022-09-11
Journal: CMAJ open [Category] COVID19(2023년), SARS, 진단, 치료법,

[키워드] 95% CI 95% confidence interval Adults age Antibody testing Asymptomatic attack rate bedroom Chain Reaction Child children Clustering conducted contribute COVID-19 COVID-19 pandemic defined Descriptive statistics eligible eligible participant emergency department enrolled enrolment enzyme enzyme-linked immunosorbent assay enzyme-linked immunosorbent assays evaluate Health policy household household contact household contacts household transmission Households IgA IgM and IgG individual media multivariable logistic regression nucleocapsid protein number of household Odds ratio outcome participant Participation Patient performed polymerase chain polymerase chain reaction positive positive result predictor Primary outcome proportion public health required reverse transcription robust SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antibody testing SARS-CoV-2 transmission secondary attack rate Spread standard error study participation study period subgroups symptomatic symptomatic and asymptomatic tested Transmission transmission of SARS-CoV-2 transmitted were used
[DOI] 10.9778/cmajo.20220026 PMC 바로가기 [Article Type] Article

Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

Clinical Trial

Published on 2022-04-082022-10-05
Journal: Critical Care [Category] COVID19(2023년), SARS, 임상,

[키워드] acute respiratory distress addition adverse event all-cause mortality all-cause mortality rate Auxora baseline calcium channel inhibitor chest imaging clinical trial Corticosteroid COVID-19 hospitalization CRAC CRAC channel inhibitor Day declining determine diagnosis of COVID-19 double-blind Efficacy endothelial integrity Enrollment enrolment groups Guidance Infection Invasive mechanical ventilation Laboratory testing less medication nasal Non-invasive occurred Oxygen therapy PaO Patient patients treated Placebo placebo-controlled trial Pneumonia polymerase chain primary endpoint Proinflammatory cytokine pulse oximetry Randomized randomized patients randomized-controlled receiving Regulatory required Respiratory failure SAE SAEs Safe secondary endpoint severe COVID-19 Severe COVID-19 pneumonia Standard of care Symptom syndrome time Time to recovery treat Treatment Trial with COVID-19
[DOI] 10.1186/s13054-022-03964-8 PMC 바로가기 [Article Type] Clinical Trial

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

Randomized Controlled Trial

Published on 2022-04-012022-10-04
Journal: Clinical microbiology and infection : the official [Category] 신약개발, 임상,

[키워드] 1:1 28-day mortality 95% CI acute respiratory syndrome Admissions adverse events assigned clinical clinical recovery clinical trial coronavirus coronavirus disease COVID-19 did not reduce double-blind double-blinded enrolment evaluate Favipiravir hazard ratio Hospital admission Hospitalization intensive care interim analysis interquartile range male matching placebo median age median time Mild mild case mild COVID-19 mild COVID-19 patient monitoring board multicentre negative RT-PCR no difference Non-severe SARS-CoV-2 Non-severe SARS-CoV-2. participant Patient PCR test PCR-confirmed Placebo placebo-controlled clinical trial placebo-controlled trial Primary outcome Randomized receive recruited reduce reducing SARS-CoV-2 Saudi Arabia secondary outcome Seven severe adverse events symptom resolution the placebo group therapy Treatment treatment group Trial two group viral clearance
[DOI] 10.1016/j.cmi.2021.12.026 PMC 바로가기 [Article Type] Randomized Controlled Trial

COVID-19 vaccine effectiveness among healthcare workers in Albania (COVE-AL): protocol for a prospective cohort study and cohort baseline data

알바니아 의료 종사자의 COVID-19 백신 효과(COVE-AL): 전향적 코호트 연구 및 코호트 기준 데이터를 위한 프로토콜

Article

Published on 2022-03-232022-09-11
Journal: BMJ Open [Category] SARS, 치료법,

[키워드] Albania All participant All participants antibody approved baseline BNT162b2 BNT162b2 mRNA board Cohort collected Comorbidities Complete completion country COVID-19 COVID-19 vaccine demographics dose Effectiveness enrolled enrolment Ethics evaluate female hazard health worker healthcare worker hospital Infection infection control infection risk laboratory-confirmed SARS-CoV-2 infection median age nucleocapsid protein participant peer-reviewed Pfizer proportional hazards model prospective cohort study protocol provided Public public health question questionnaire reference number registration number review RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein serology seropositive Spike protein Study protocol Swab Symptom symptomatic participant symptomatic participants tested the SARS-CoV-2 the WHO written Informed Consent
[DOI] 10.1136/bmjopen-2021-057741 PMC 바로가기 [Article Type] Article

A look back at the first wave of COVID-19 in China: A systematic review and meta-analysis of mortality and health care resource use among severe or critical patients

Research Article

Published on 2022-03-112022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial

Randomized Controlled Trial

Published on 2022-03-012022-10-04
Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 바이오마커, 임상, 치료법,

[키워드] 1:1 age Analysis anti-SARS-CoV-2 IgG assigned baseline convalescent plasma COVID-19 COVID-19 vaccine crowdfunding did not reduce double-blind early treatment Efficacy eligible Endpoint enrolment Euroimmun Evidence experimental group experimental intervention for inclusion Grifols health-care hospitalisation in viral incidence intention-to-treat population intravenous IQR less log Methylene Mild mild COVID-19 symptom monitoring board multicentre Nasopharyngeal swab occurred Older Outpatient participant Patient Placebo placebo-controlled trial plasma Prevent progression random assignment randomisation randomised Randomly receive recommendation reduce Registered reported risk saline solution SARS-CoV-2 viral load Serious Adverse Event severe disease Spain Stratification Support symptom duration the mean Thromboembolic event titre Treatment Trial Viral load was done web-based system with COVID-19
[DOI] 10.1016/S2213-2600(21)00545-2 PMC 바로가기 [Article Type] Randomized Controlled Trial

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

캐나다에서 COVID-19로 병원에 입원한 환자의 치료를 위한 Remdesivir: 무작위 대조 시험

Randomized Controlled Trial

Published on 2022-02-222022-09-11
Journal: CMAJ : Canadian Medical Association journal = jour [Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] 95% CI 95% confidence interval adverse event age Analysis assigned baseline Canada changes in Characteristics clinical outcomes Clinical severity conjunction Consent Controlled trial COVID-19 creatinine Data collection defined demographics dialysis duration of symptom Effect enrolment evaluated event followed by groups Health care health care systems Health Organization health systems hepatic dysfunction hospital Hospital mortality Hospital stay hospitals in-hospital mortality incidence intravenously mechanical ventilation mechanically ventilated Mortality no difference Open-label outcome oxygen Patient patients performed Pragmatic Primary outcome Randomized Randomized controlled trial randomized patient RCT receive receiving Relative risk Remdesivir risk secondary Secondary outcomes severity of symptom Sex significant effect solidarity Solidarity trial standard care Standard deviation Standard of care Standard-of-care Treatment Trial Trial registration ventilator-free day Ventilator-free days with COVID-19 World Health Organization
[DOI] 10.1503/cmaj.211698 PMC 바로가기 [Article Type] Randomized Controlled Trial

Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)

SARS-COV-2에 대한 예방 접종 전 항체 반응의 결정 인자 : 인구 기반 종단 연구 (Covidence UK)

Research Article

Published on 2022-02-222022-09-01
Journal: BMC Medicine [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단,

[키워드] 95% CI adjusted adjusted odds ratio adjusted odds ratios alcohol alcohol consumption All participants anti-spike antibodies antibody Antibody Response Antibody titre antibody titres association behavioural BMI body mass body mass index COVID-19 disease COVID-19 disease severity determinant diet dried blood spot Dried blood spots enrolment Ethnicity exercise explained Factor geometric mean geometric mean ratio geometric mean ratios greater groups higher risk IgM responses independent independent of International investigated lifestyle LIGHT Linear regression Logistic lower risk micronutrients obese obesity Occupation online questionnaires participant Participants pharmacological physical Physical exercise positive swab pre-vaccination Prospective recruited response Result risk risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike glycoprotein serology seropositive seropositive participants Seropositivity Sociodemographic South Asian spike glycoprotein supplementary material test result titre Travel was obtained white
[DOI] 10.1186/s12916-022-02286-4 PMC 바로가기 [Article Type] Research Article